DSpace DSpace Softwareについて
 

GINMU >
01 奈良県立医科大学 >
012 大学院 >
0122 学位請求論文 >
01221 博士論文(医学) >
2016年度 >

このアイテムの引用には次の識別子を使用してください: http://hdl.handle.net/10564/3320

タイトル: Tumor-inhibition effect of levetiracetam in combination with temozolomide in glioblastoma cells.
その他のタイトル: 膠芽腫細胞株におけるテモゾロミド併用によるレベチラセタムの抗腫瘍効果
著者: Marutani, Akiko
Nakamura, Mitsutoshi
Nishimura, Fumihiko
Nakazawa, Tsutomu
Matsuda, Ryosuke
Hironaka, Yasuo
Nakagawa, Ichiro
Tamura, Kentaro
Takeshima, Yasuhiro
Motoyama, Yasushi
Boku, Eishu
Ouji, Yukiteru
Yoshikawa, Masahide
Nakase, Hiroyuki
キーワード: temozolomide
levetiracetam
premature senescence
glioblastoma
発行日: 2017年1月
出版者: Springer
引用: Neurochemical Journal Vol.11 No.1 p.43-49 (2017 Jan)
抄録: Glioblastoma (GBM) is a malignant brain tumor with a poor prognosis. The standard postoperative chemotherapy is temozolomide (TMZ), which does not greatly improve survival. The DNA repair gene O-6-methylguanine-DNA methyltransferase (MGMT) contributes to the response of TMZ-induced DNA damage. The commonly prescribed antiepileptic drug levetiracetam (LEV) has been shown to enhance TMZ’s antitumor effect via inhibition of histone deacetylases (HDACs), but the therapeutic advantages of the LEV and TMZ combination remain poorly understood. Mechanisms of response to chemotherapy include apoptosis and mitotic catastrophe, and recent studies have suggested that premature senescence may also be invoked when cancer cells are exposed to therapeutic agents. In our study, we evaluated cell proliferation and premature senescence after single and combined treatments of TMZ and LEV in two GBM cell lines that differ in TMZ sensitivity caused by the absence (A172) or presence (T98) of the MGMT protein. Both LEV and TMZ reduced cell proliferation in a dose-dependent manner in A172 cells. A senescent-like phenotype, as determined by β-galactosidase activity, was induced by both TMZ and LEV. Overall, there was a greater effect following combined treatment compared to the monotherapy groups. Thus, LEV appears to have a tumor-suppressive effect and induces cellular senescence, and combined treatment of LEV and TMZ enhanced these effects. because LEV treatment results in few adverse effects, its use in GBM treatment may allow for reduction of the TMZ dose to enhance the clinical efficacy of TMZ chemotherapy and improve quality of life.
内容記述: 博士(医学)・甲第667号・平成29年3月15日
© Pleiades Publishing, Ltd. 2017
The final publication is available at Springer via http://dx.doi.org/10.1134/S1819712416040073
発行元が定める登録猶予期間終了の後、本文を登録予定(2018.1)
URI: http://hdl.handle.net/10564/3320
ISSN: 18197124
学位授与番号: 24601A667
学位授与年月日: 2017-03-15
学位名: 博士(医学)
学位授与機関: 奈良県立医科大学
出現コレクション:2016年度

このアイテムのファイル:

ファイル 記述 サイズフォーマット
01 甲667本文の要旨.pdf甲667本文の要旨133.52 kBAdobe PDF見る/開く
02 甲667審査要旨.pdf甲667審査要旨287.66 kBAdobe PDF見る/開く

このリポジトリに保管されているアイテムは、他に指定されている場合を除き、著作権により保護されています。

 

Valid XHTML 1.0! Powered by DSpace Software Copyright © 2002-2007 MIT and Hewlett-Packard - ご意見をお寄せください